Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Given the last day of the trading for 2006, initiations were light. - Baird initiated Noven Pharmaceuticals (NASDAQ: NOVN) with an Outperform and $30 target, based on the Daytrana, which Baird believes should be a driver for shares with continued success, milestones and improved profitability.
- Also initiated by Baird, POZEN Inc (NASDAQ: POZN) with an Outperform rating and $26 target; they expect Pozen's Trexima to be approved in mid-2007 and for their marketing partner, GlaxoSmithKline plc ADR (NYSE: GSK), to convert 60% of Imitrix market share to Trexima.
- Thomas Weisel initiated Hansen Medical (NASDAQ: HNSN) with an Overweight rating and $14.50 target; the firm is positive on the Sensai platform, a robotic catheter control system, which allows unprecedented control and enables new procedures to become minimally invasive.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
